Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Editas Medicine Appoints Dan Ory, M.D. As Chief Medical Officer

PUBLIC · EDITSep 08, 2026•about 2 hours ago

Position

Chief Medical Officer

Company

Editas Medicine

Dan Ory, M.D.
CambrdigeBiotechnologyHealth Care

Description

Editas Medicine announced the appointment of Dan Ory, M.D., as Chief Medical Officer. Dr. Ory will lead the company's clinical development strategy and oversee the advancement of EDIT-401 towards clinical trials.

Company Information

Company

Editas Medicine

Location

Cambrdige, Massachusetts, United States

About

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translateearly findings into viable human therapeutic products.

Don't miss Editas Medicine's next move

Get an email the moment Editas Medicine changes its leadership, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
Caren
Likely contact at this company
••••••••@••••••••

See Caren's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Editas Medicine's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Editas Medicine changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.